Last reviewed · How we verify
NCT06146738: PALSUR
The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)
trial testing Palliative Care in Glioblastoma in 1,015 participants. Currently enrolling.
1 January 2028
Quick facts
| Lead sponsor | Jasper Gerritsen |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 1,015 |
| Start date | 1 January 2023 |
| Primary completion | 1 January 2028 |
| Estimated completion | 1 January 2029 |
| Sites | 8 locations across Netherlands, Belgium, Germany, Switzerland, United States |
Drugs / interventions tested
- Palliative Care — full drug profile →
- Tumor biopsy
- Tumor resection
Conditions studied
- Glioblastoma — all drugs for Glioblastoma →
- Glioblastoma Multiforme — all drugs for Glioblastoma Multiforme →
- Glioblastoma, IDH-wildtype — all drugs for Glioblastoma, IDH-wildtype →
- Glioblastoma Multiforme, Adult — all drugs for Glioblastoma Multiforme, Adult →
Sponsor
Jasper Gerritsen
Who can join
Adults 18 to 90, any sex, with Glioblastoma or Glioblastoma Multiforme. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
There is no consensus on the optimal treatment of patients with high-grade glioma, especially when patients have limited functioning performance at presentation (KPS ≤70). Therefore, there are varied practice patterns around pursuing biopsy, resection, or palliation (best supportive care). This study aims to characterize the impact of palliative care versus biopsy versus resection on survival and quality of life in these patients. Also, it will aim to determine if there is a subset of patients that benefit the most from resection or biopsy, for which outcome, and how they could be identified preoperatively. This study is an international, multicenter, prospective, 3-arm cohort study of observational nature. Consecutive HGG patients will be treated with palliative care, biopsy, or resection at a 1:3:3 ratio. Primary endpoints are: 1) overall survival, and 2) quality of life at 6 weeks, 3 months and 6 months after initial presentation based on the EQ-5D, EORTC QLQ C30 and EORTC BN 20 questionnaires. Total duration of the study is 5 years. Patient inclusion is 4 years, follow-up is 1 year.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06146738
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Palliative Care
Trials testing the same drug.
- NCT05646576 — Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy · NA · recruiting
- NCT04248244 — Effects of Early Palliative Care Integration on Patients With Newly Diagnosed Multiple Myeloma · NA · completed
- NCT03540771 — Introducing Palliative Care (PC) Within the Treatment of End Stage Liver Disease (ESLD) · NA · completed
- NCT03471546 — Early Palliative Care Intervention in Malignant Glioma · NA · completed
- NCT03310918 — A Collaborative Palliative and Leukemia Care Model for Patients With AML and MDS Receiving Non-Intensive Therapy · NA · active not recruiting
Other recruiting trials for Glioblastoma
Currently open trials in the same condition.
- NCT07284069 — Senicapoc and Perampanel for Newly Diagnosed Glioblastoma · EARLY_PHASE1 · recruiting
- NCT05653635 — Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study · Phase 2 · recruiting
- NCT07480941 — Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma · Phase 1 · recruiting
- NCT07448480 — Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas · active not recruiting
- NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
Other Jasper Gerritsen trials
Trials by the same sponsor.
- NCT06283927 — The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302) · recruiting
- NCT06146725 — The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202) · recruiting
- NCT06118723 — The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201) · recruiting
- NCT03861299 — The SAFE-Trial: Awake Craniotomy Versus Surgery Under General Anesthesia for Glioblastoma Patients. · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06146738 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jasper Gerritsen
- Last refreshed: 27 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06146738.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing